{"schema_version":"secwatch.filing_event.v1","accession":"0000950142-22-001844","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2022-06-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.987501+00:00","generated_at":"2026-06-25T03:34:13.029192+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"NRx Pharmaceuticals appoints Seth Van Voorhees as CFO and Treasurer, effective June 13, 2022","bullets":["Van Voorhees most recently CFO of PDS Biotechnology; prior CFO at Research Frontiers and American Pacific.","Employment agreement: $400k annual base salary, $200k target bonus, and option grant for 325,000 shares with two-year vesting.","Severance: nine months' salary plus prorated bonus and accelerated vesting on termination without cause or change of control.","Company focusing resources on psychiatry franchise, particularly NRX-101 for bipolar depression with suicidality."],"urls":{"canonical":"https://secwatch.observer/filing/0000950142-22-001844","json":"https://secwatch.observer/filing/0000950142-22-001844.json","markdown":"https://secwatch.observer/filing/0000950142-22-001844.md","text":"https://secwatch.observer/filing/0000950142-22-001844.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000095014222001844/0000950142-22-001844-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000095014222001844/eh220259882_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T03:34:13.029192+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c08673868f","claim":"Dr. Seth Van Voorhees was appointed as Chief Financial Officer and Treasurer at NRX Pharmaceuticals, Inc..","evidence_excerpt":"On June 6, 2022, the Board of Directors of NRx Pharmaceuticals, Inc. (the “ Company ”) appointed Dr. Seth Van Voorhees, 61, to serve as Chief Financial Officer (“CFO”) and Treasurer of the Company, effective June 13, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000095014222001844/0000950142-22-001844-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer and Treasurer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}